Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more
Camurus AB (CAMX) - Net Assets
Latest net assets as of December 2025: Skr4.24 Billion SEK
Based on the latest financial reports, Camurus AB (CAMX) has net assets worth Skr4.24 Billion SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr4.74 Billion) and total liabilities (Skr504.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr4.24 Billion |
| % of Total Assets | 89.36% |
| Annual Growth Rate | 52.46% |
| 5-Year Change | 398.93% |
| 10-Year Change | 650.41% |
| Growth Volatility | 121.63 |
Camurus AB - Net Assets Trend (2011–2025)
This chart illustrates how Camurus AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Camurus AB (2011–2025)
The table below shows the annual net assets of Camurus AB from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr4.24 Billion | +28.75% |
| 2024-12-31 | Skr3.29 Billion | +120.34% |
| 2023-12-31 | Skr1.49 Billion | +50.10% |
| 2022-12-31 | Skr994.67 Million | +17.17% |
| 2021-12-31 | Skr848.91 Million | +0.17% |
| 2020-12-31 | Skr847.44 Million | +34.17% |
| 2019-12-31 | Skr631.63 Million | +150.33% |
| 2018-12-31 | Skr252.32 Million | -34.46% |
| 2017-12-31 | Skr385.00 Million | -31.79% |
| 2016-12-31 | Skr564.42 Million | -11.89% |
| 2015-12-31 | Skr640.56 Million | +418.85% |
| 2014-12-31 | Skr123.46 Million | +146.68% |
| 2013-12-31 | Skr50.05 Million | +24.46% |
| 2012-12-31 | Skr40.21 Million | +248.29% |
| 2011-12-31 | Skr11.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Camurus AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 63309500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr610.44 Million | 14.41% |
| Common Stock | Skr1.50 Million | 0.04% |
| Other Components | Skr3.62 Billion | 85.55% |
| Total Equity | Skr4.24 Billion | 100.00% |
Camurus AB Competitors by Market Cap
The table below lists competitors of Camurus AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Land and Houses Public Company Limited
OTCGREY:LDHOF
|
$1.54 Billion |
|
Spectrum Brands Holdings Inc
NYSE:SPB
|
$1.54 Billion |
|
BRDNF
PINK:BRDNF
|
$1.54 Billion |
|
Chengdu Wintrue Holding Co Ltd
SHE:002539
|
$1.54 Billion |
|
Shanghai Phichem Material Co Ltd Class A
SHE:300398
|
$1.54 Billion |
|
Shenzhen Ysstech Info-Tech Co Ltd
SHE:300377
|
$1.54 Billion |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
$1.54 Billion |
|
Carmila SA
PA:CARM
|
$1.54 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Camurus AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,289,681,000 to 4,235,415,000, a change of 945,734,000 (28.7%).
- Net income of 735,568,000 contributed positively to equity growth.
- Share repurchases of 76,000 reduced equity.
- New share issuances of 176,524,000 increased equity.
- Other comprehensive income decreased equity by 5,199,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr735.57 Million | +17.37% |
| Share Repurchases | Skr76.00K | -0.0% |
| Share Issuances | Skr176.52 Million | +4.17% |
| Other Comprehensive Income | Skr-5.20 Million | -0.12% |
| Other Changes | Skr38.92 Million | +0.92% |
| Total Change | Skr- | 28.75% |
Book Value vs Market Value Analysis
This analysis compares Camurus AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 479.21x to 6.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.98 | Skr471.00 | x |
| 2013-12-31 | Skr1.22 | Skr471.00 | x |
| 2014-12-31 | Skr3.02 | Skr471.00 | x |
| 2015-12-31 | Skr15.73 | Skr471.00 | x |
| 2016-12-31 | Skr13.78 | Skr471.00 | x |
| 2017-12-31 | Skr9.26 | Skr471.00 | x |
| 2018-12-31 | Skr6.00 | Skr471.00 | x |
| 2019-12-31 | Skr13.58 | Skr471.00 | x |
| 2020-12-31 | Skr16.09 | Skr471.00 | x |
| 2021-12-31 | Skr15.59 | Skr471.00 | x |
| 2022-12-31 | Skr18.06 | Skr471.00 | x |
| 2023-12-31 | Skr25.97 | Skr471.00 | x |
| 2024-12-31 | Skr55.29 | Skr471.00 | x |
| 2025-12-31 | Skr70.58 | Skr471.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Camurus AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.37%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 32.47%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.12x
- Recent ROE (17.37%) is above the historical average (5.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 33.12% | 13.99% | 1.66x | 1.43x | Skr9.30 Million |
| 2013 | 198.28% | 50.19% | 1.77x | 2.23x | Skr94.23 Million |
| 2014 | 39.16% | 23.22% | 1.00x | 1.68x | Skr36.00 Million |
| 2015 | -24.91% | -103.06% | 0.19x | 1.27x | Skr-223.60 Million |
| 2016 | -14.35% | -71.21% | 0.18x | 1.13x | Skr-137.43 Million |
| 2017 | -49.50% | -350.91% | 0.11x | 1.24x | Skr-229.07 Million |
| 2018 | -93.01% | -475.81% | 0.14x | 1.45x | Skr-259.91 Million |
| 2019 | -45.89% | -274.48% | 0.14x | 1.22x | Skr-353.03 Million |
| 2020 | -19.74% | -49.78% | 0.32x | 1.23x | Skr-252.01 Million |
| 2021 | -10.65% | -15.06% | 0.56x | 1.27x | Skr-175.34 Million |
| 2022 | 5.59% | 5.81% | 0.73x | 1.31x | Skr-43.91 Million |
| 2023 | 28.90% | 25.13% | 0.90x | 1.28x | Skr282.14 Million |
| 2024 | 13.02% | 22.94% | 0.50x | 1.14x | Skr99.43 Million |
| 2025 | 17.37% | 32.47% | 0.48x | 1.12x | Skr312.03 Million |
Industry Comparison
This section compares Camurus AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Camurus AB (CAMX) | Skr4.24 Billion | 33.12% | 0.12x | $1.54 Billion |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |